Quarterly report pursuant to Section 13 or 15(d)

CONCENTRATIONS

v3.2.0.727
CONCENTRATIONS
6 Months Ended
Jun. 30, 2015
Notes to Financial Statements  
Note 17 - CONCENTRATIONS

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. 

 

The Company’s revenues earned from sale of products and services for the three months ended June 30, 2015 included 22%, 23% and 11% (aggregate of 56%) from three customers of the Company’s total revenues. 

 

The Company’s revenues earned from sale of products and services for the six months ended June 30, 2015 included 16%, 27%, 10% and 13% (aggregate of 66%) from four customers of the Company’s total revenues. 

 

The Company’s revenues earned from sale of products and services for the three months ended June 30, 2014 included 13%, 52% and 26% (aggregate of 91%) from three customers of the Company’s total revenues. 

  

The Company’s revenues earned from sale of products and services for the six months ended June 30, 2014 included 10%, 42% and 40% (aggregate of 92%) from three customers of the Company’s total revenues. 

 

One customer accounted for 53% of the Company’s total accounts receivable at June 30, 2015 and three customers accounted for 65%, 16% and 10% of the Company’s total accounts receivable at December 31, 2014. 

 

The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant.